Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

ALS newco QurAlis launches

April 6, 2018 5:49 PM UTC

Amyotrophic lateral sclerosis company QurAlis Corp. (Cambridge, Mass.) debuted with seed funding from MP Healthcare Venture Management, Amgen Ventures and Alexandria Venture Investments. QurAlis CEO Kasper Roet declined to disclose financial terms.

QurAlis is targeting three ALS subtypes. The company has two preclinical therapeutic programs, and is developing a device to remove toxic proteins from the brain and cerebral spinal fluid...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article